Navigation Links
Promega and Cellular Dynamics Partner to Validate Stem Cell-Based In Vitro Assays for Predicting Drug-Induced Cardiotoxicity
Date:6/15/2010

Cellular Dynamics International (CDI) and Promega have entered into a research collaboration with the goal of bringing more relevant and highly predictive toxicity testing to the drug discovery process.

Madison, WI (PRWEB) June 15, 2010 -- Cellular Dynamics International (CDI) and Promega have entered into a research collaboration with the goal of bringing more relevant and highly predictive toxicity testing to the drug discovery process. Pharmaceutical discovery scientists will now be able to combine bioassays with human cardiomyocytes to improve prediction of unintentional, detrimental side effects that have previously remained undetected until late in the development process or after release of the drug to the general public.

Currently CDI has validated a panel of cell-based cytotoxicity assays from Promega that use CDI’s human induced pluripotent stem (iPS) cell-derived iCellTM Cardiomyocytes. Data presented at the recent Society of Toxicology and the Society of Biomolecular Sciences conferences by CDI demonstrate that Promega’s multiplexed biomarker assays for cytotoxicity and cell viability can be used to identify known toxic agents with similar sensitivity as reported in the published literature (see figure).

CDI and its pharmaceutical collaborators have begun validating such assays in order to incorporate them into their routine discovery programs. Chris Parker, CDI’s chief commercial officer, noted, “Pharmaceutical customers recognize the importance of using human models to perform their studies—but up until recently, human cell models that exhibited true human biology in vitro were difficult to come by. We have several pharmaceutical customers who’ve validated in vitro cardiotoxicity assays using iCell Cardiomyocytes, which have correlated well with previous data from cardiotoxicity studies in animal-based models.” Ultimately, the union of these two technologies from Promega and CDI is expected to provide more biologically predictive data and drive the development of safer and more effective drugs.

About Promega
Promega Corporation is a leader in providing innovative solutions and technical support to the life sciences industry. The company’s 2,000 products enable scientists worldwide to advance their knowledge in genomics, proteomics, cellular analysis, molecular diagnostics and human identification. Founded in 1978, the company is headquartered in Madison, WI, USA with branches in 14 countries and over 50 global distributors. For more information about Promega, visit www.promega.com.

About Cellular Dynamics International
Cellular Dynamics International, Inc. (CDI) is a leading developer and marketer of next-generation stem cell technologies for drug development and personalized medicine applications. CDI harnesses the power of pluripotent stem cells and their ability to differentiate into any cell type for world-class drug development tools. In addition, it is the leader in iPSC technology, the production of pluripotent stem cell lines from adult tissue. CDI was founded in 2004 by James Thomson, a pioneer in human pluripotent stem cell research at the University of Wisconsin-Madison, and Tactics II Ventures, a Wisconsin-based private equity fund. CDI’s facilities are located in Madison, Wisconsin. See www.cellulardynamics.com.

# # #

Read the full story at http://www.prweb.com/releases/2010/06/prweb4138444.htm.


'/>"/>
Source: PRWeb
Copyright©2010 Vocus, Inc.
All rights reserved  

Related biology technology :

1. New Promega Maxwell 16 LEV Blood DNA Kit Surpasses Concentration Standards in Less Time
2. NDIS Approval of Promega PowerPlex Kit Clears Path for More DNA Profiles to be Added to U.S. Database
3. Promega and SwitchGear Publish Findings from Combined Technologies that Correlate Binding Events and Transcriptional Activity
4. Promega HaloTag Protein Purification System Makes it Easier to Purify Difficult-to-Express Proteins
5. New STR Systems from Promega Comply with Latest DNA Database Standards
6. Celsis In Vitro Technologies and Promega to Offer Fast, Reliable Solutions for ADME-Tox Testing With Primary Hepatocytes
7. Tengion Presents New Data Supporting Key Urologic and Kidney Programs at 16th Annual Meeting of the International Society for Cellular Therapy
8. t2cure First Company to Have Quality of Cellular Therapeutic Certified by EMA
9. iPierian Awarded Basic Biology Grant by California Institute of Regenerative Medicine to Study Cellular Reprogramming
10. Cellular Dynamics and Roche Conduct Stem Cells in Drug Discovery and Development Workshop at the Society of Toxicology Annual Meeting
11. Aegera Therapeutics Initiates a Randomized Phase 2 Study with AEG35156 for the Treatment of Hepatocellular Carcinoma
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Promega and Cellular Dynamics Partner to Validate Stem Cell-Based In Vitro Assays for Predicting Drug-Induced Cardiotoxicity 
(Date:2/11/2016)... Florida , February 11, 2016 ... PositiveID Corporation ("PositiveID" or "Company") (OTCQB: PSID), a ... announced today that its Thermomedics subsidiary, which markets ... on its growth plan in January 2016, including ... distributors, increasing sequential monthly sales growth, and establishing ...
(Date:2/10/2016)... /PRNewswire/ - BioAmber Inc. (NYSE: BIOA ), a ... Mitsui & Co. Ltd., its partner in the ... investing an additional CDN$25 million in the joint venture ... 30% to 40%.  Mitsui will also play a stronger ... Sarnia , providing dedicated resources alongside ...
(Date:2/10/2016)... ... February 10, 2016 , ... ... that it has joined the Human Vaccines Project, a public-private partnership to ... cancer. , The Human Vaccines Project brings together leading pharmaceutical and ...
(Date:2/10/2016)... (PRWEB) , ... February 10, 2016 , ... ... attend the International Society of Pharmaceutical Engineering (ISPE) Rocky Mountain Chapter 21st Annual ... is expecting to fill more than 100 tables for its annual event, which ...
Breaking Biology Technology:
(Date:1/13/2016)... , January 13, 2016 ... has published a new market report titled - Biometric Sensors ... and Forecast, 2015 - 2023. According to the report, the global ... and is anticipated to reach US$1,625.8 mn by 2023, ... 2023. In terms of volume, the biometric sensors market ...
(Date:1/11/2016)... Synaptics Incorporated (NASDAQ: SYNA ), the ... its ClearPad ® TouchView ™ 4300 touch ... categories in the 8 th Annual Mobile Excellence ... The Synaptics ® TDDI solution enables faster time-to-market, ... devices, brighter displays and borderless designs. ...
(Date:1/8/2016)... MANCHESTER, United Kingdom , Jan. 8, 2016 ... innovative sensor-based diagnostic products, today announced the closing of a ... existing investors.  Proceeds from the financing will be used to ... hand-held device for detecting early-stage pressure ulcers. ... after receiving CE Mark approval. The device,s introduction has ...
Breaking Biology News(10 mins):